Next Article in Journal
Development of mRNA Vaccines: Scientific and Regulatory Issues
Next Article in Special Issue
Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic Review
Previous Article in Journal
Influenza Vaccine Effectiveness in Mainland China: A Systematic Review and Meta-Analysis
Previous Article in Special Issue
Cost-Effectiveness Analysis of BCG Vaccination against Tuberculosis in Indonesia: A Model-Based Study
 
 
Article

Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States

1
Seqirus USA Inc., Summit, NJ 07901, USA
2
IQVIA, Falls Church, VA 22042, USA
3
Unit of PharmacoTherapy, Epidemiology & Economics (PTE2), Department of Pharmacy, University of Groningen, 9700 Groningen, The Netherlands
4
Department of Health Sciences, University Medical Centre Groningen (UMCG), University of Groningen, 9700 Groningen, The Netherlands
5
Department of Economics, Econometrics & Finance, Faculty of Economics & Business, University of Groningen, 9700 Groningen, The Netherlands
6
Department of Epidemiology, Boston University Schools of Medicine and Public Health, Boston, MA 02118, USA
7
Maxwell Finland Laboratories, Boston Medical Center, Boston, MA 02118, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Ralph A. Tripp
Vaccines 2021, 9(2), 80; https://doi.org/10.3390/vaccines9020080
Received: 7 December 2020 / Revised: 16 January 2021 / Accepted: 17 January 2021 / Published: 23 January 2021
(This article belongs to the Special Issue Health Economics of Vaccines)
Non-egg-based influenza vaccines eliminate the potential for egg-adapted mutations and potentially increase vaccine effectiveness. This retrospective study compared hospitalizations/emergency room (ER) visits and all-cause annualized healthcare costs among subjects aged 4–64 years who received cell-based quadrivalent (QIVc) or standard-dose egg-based quadrivalent (QIVe-SD) influenza vaccine during the 2018–19 influenza season. Administrative claims data (IQVIA PharMetrics® Plus, IQVIA, USA) were utilized to evaluate clinical and economic outcomes. Adjusted relative vaccine effectiveness (rVE) of QIVc vs. QIVe-SD among overall cohort, as well as for three subgroups (age 4–17 years, age 18–64 years, and high-risk) was evaluated using inverse probability of treatment weighting (IPTW) and Poisson regression models. Generalized estimating equation models among the propensity score matched sample were used to estimate annualized all-cause costs. A total of 669,030 recipients of QIVc and 3,062,797 of QIVe-SD were identified after IPTW adjustments. Among the overall cohort, QIVc had higher adjusted rVEs against hospitalizations/ER visits related to influenza, all-cause hospitalizations, and hospitalizations/ER visits associated with any respiratory event compared to QIVe-SD. The adjusted annualized all-cause total costs were higher for QIVe-SD compared to QIVc ((+$461); p < 0.05). View Full-Text
Keywords: influenza vaccine; cell-based; egg-based; relative vaccine effectiveness; retrospective studies; economic assessment; real-world evidence influenza vaccine; cell-based; egg-based; relative vaccine effectiveness; retrospective studies; economic assessment; real-world evidence
Show Figures

Figure 1

MDPI and ACS Style

Krishnarajah, G.; Divino, V.; Postma, M.J.; Pelton, S.I.; Anupindi, V.R.; DeKoven, M.; Mould-Quevedo, J. Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States. Vaccines 2021, 9, 80. https://doi.org/10.3390/vaccines9020080

AMA Style

Krishnarajah G, Divino V, Postma MJ, Pelton SI, Anupindi VR, DeKoven M, Mould-Quevedo J. Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States. Vaccines. 2021; 9(2):80. https://doi.org/10.3390/vaccines9020080

Chicago/Turabian Style

Krishnarajah, Girishanthy, Victoria Divino, Maarten J. Postma, Stephen I. Pelton, Vamshi Ruthwik Anupindi, Mitch DeKoven, and Joaquin Mould-Quevedo. 2021. "Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States" Vaccines 9, no. 2: 80. https://doi.org/10.3390/vaccines9020080

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop